
Q&A With Erich Spangenberg On Patents And Drug Prices
Prices for drugs have long been a problem for developing countries but now have become out of reach for many in developed countries, sparking policy debates and efforts to address it. One of the top figures in the patent monetization business, industry maverick Erich Spangenberg offers a lively opinion on the underlying problem and how to fix it. To start? Stop granting patent extensions for minor changes.









